The Effectiveness of Diabetic Foot Wound Prevention Training Given with Pecha Kucha (20*20) Presentation Technique: A Randomized Controlled.

Int J Low Extrem WoundsFeb 13, 2025 (epub)
Clinical ResearchEndocrinology

Berna Dincer, Ceren Kocali, Tuba Elveren et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled study assessed whether diabetic foot care education delivered with the Pecha Kucha (20×20) presentation method improved knowledge, self-efficacy, and self-care behavior among 125 people with type 2 diabetes. The 62 participants in the experimental group received Pecha Kucha education; 63 controls received conventional education. The experimental group had significantly higher knowledge and self-efficacy scores than controls (p < 0.001), but self-care behavior scores did not differ significantly (p > 0.05). The findings indicate gains in educational outcomes, without evidence of a corresponding behavioral difference in this study.

Key findings

  • Knowledge scores were significantly higher after Pecha Kucha education than conventional education (p < 0.001).
  • Self-efficacy scores were significantly higher in the experimental group than in controls (p < 0.001).
  • Foot self-care behavior scores did not differ significantly between groups (p > 0.05).

Why it matters

Foot-care education is intended to support prevention, but improved knowledge and confidence do not necessarily translate into changed self-care behavior. This trial suggests that a structured, brief presentation format can improve these educational outcomes compared with conventional education, while highlighting the need to assess whether such gains lead to sustained behavioral change.

What to keep in mind

The abstract reports no significant difference in self-care behavior and calls for further research on long-term behavioral effects; long-term impact is therefore not established.

Source

Published in Int J Low Extrem Wounds. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.